BBHC
AIMT

Brown Brothers Harriman & Co’s Aimmune Therapeutics AIMT Stock Holding History

Brown Brothers Harriman & Co’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-222
Closed -$5K – 842
2017
Q1 		$5K Hold
222
– – ﹤0.01% 727
2016
Q4 		$5K Hold
222
– – ﹤0.01% 773
2016
Q3 		$3K Hold
222
– – ﹤0.01% 738
2016
Q2 		$2K Buy
+222
New +$3.02K ﹤0.01% 800

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Brown Brothers Harriman & Co's AIMT Position: Q2 2017 in Review

Brown Brothers Harriman & Co sold out of Aimmune Therapeutics (AIMT) in Q2 2017, closing a stake of 222 shares — an estimated $5K sold.

Brown Brothers Harriman & Co first reported a position in AIMT in Q2 2016 and held it in 4 quarters. The position peaked at $5K in Q1 2017. 96 funds tracked by Wall St. Rank hold AIMT as of Q2 2017.

  • Brown Brothers Harriman & Co reported no remaining Aimmune Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 222 Aimmune Therapeutics shares in Q2 2017, an estimated $5K.
  • Brown Brothers Harriman & Co first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 4 quarters.
  • Brown Brothers Harriman & Co's Aimmune Therapeutics position peaked at $5K in Q1 2017.
  • 96 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2017.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2017, filed 14 Aug 2017.